New drug combo tested for dual threat: diabetes and fatty liver

This study is testing whether adding a medication called alogliptin to a standard two-drug diabetes pill (pioglitazone + metformin) works better for people who have both type 2 diabetes and fatty liver disease. Researchers will enroll 80 participants to see if the three-drug combination improves blood sugar, cholesterol, and how well the pancreas works, compared to the standard two-drug pill alone. The goal is to find a more effective way to manage these two connected conditions.